Employers should note two August 26 decisions from the National Labor Relations Board that limit their power to implement changes during first contract negotiations and after a collective bargaining agreement (CBA) has expired. These decisions — Wendt and Tecnocap — overrule a 2017 case that gave employers latitude to make operational changes following the expiration of a CBA. What do employers need to know about these rulings? Here are the answers to your top six questions.
At a September 11 public meeting, AGC shared its concerns and recommendations regarding the White House Council on Environmental Quality’s (CEQ) proposed Phase 2 revisions to the National Environmental Policy Act (NEPA) Implementing Regulations. AGC is concerned that the proposed revisions could complicate and prolong infrastructure projects, jeopardizing the potential benefits of recent legislative acts. Delays can increase project costs and even lead to abandonment. Efficiency is essential for timely community benefits, resilience, and economic strength.
Each year, in partnership with WTW and Milwaukee Tool, AGC recognizes outstanding companies and professionals in the industry for their passion and commitment to safety through the:
On September 11, AGC, along with industry partners on the Construction Industry Safety Coalition (CISC), submitted comments on Mine Safety and Health Administration’s (MSHA) proposal to update its existing standards to better protect miners against occupational exposure to respirable crystalline silica.
Construction Attorneys Who Research State Laws for the AGC/ABA State Law Matrix on a Volunteer Basis
AGC member Marathon Construction hosts Rep. Mike Levin (D-CA) for a project tour of the San Dieguito Lagoon Wetland Restoration Project in San Diego, California.
On August 29, the Department of Health and Human Services (HHS) sent a letter to the Drug Enforcement Agency (DEA) requesting that marijuana be rescheduled under the Controlled Substance Act (CSA). The health agency recommended that marijuana be reclassified from a Schedule I drug under the CSA to a Schedule III drug.